SCHEMBL2846531

SCHEMBL2846531

C[Si](C)(C)CCOCn1c(CCC(=O)O)nc(-c2ccccc2)c1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 6/20 0.43
F11 P03951 1/20 0.42
RXRA P19793 7/20 0.41
RXRB P28702 6/20 0.41
HDAC6 Q9UBN7 4/20 0.40
RXRG P48443 3/20 0.40
NR4A2 P43354 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ABCC4 O15439 1/20 0.40
C5 P01031 1/20 0.40
LMNA P02545 1/20 0.40
CHRM2 P08172 1/20 0.40
CYP3A4 P08684 1/20 0.40
CHRM1 P11229 1/20 0.40
DRD2 P14416 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
TBXA2R P21731 1/20 0.40
NR4A1 P22736 1/20 0.40
PTGS1 P23219 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2840916 0.90 FAAH (0.53) FAAHF11KDM4EMEN1KMT2A
SCHEMBL2842517 0.89 HDAC6 (0.40) F11RXRARXRBHDAC6NR4A2
SCHEMBL9370452 0.81 FAAH (0.41) FAAHF11KDM4ENPC1
SCHEMBL9369648 0.77 FAAH (0.40) FAAH
SCHEMBL4069849 0.77 F11 (0.39) FAAHF11KDM4ELMNACYP3A4
SCHEMBL4083512 0.76 F11 (0.42) F11KDM4ELMNADRD2TBXA2R
SCHEMBL9525207 0.75 MAPK14 (0.43) F11KDM4ELMNAPTGS1PTGS2
SCHEMBL16497631 0.74 MEN1 (0.45) F11MEN1KMT2ANPC1
SCHEMBL9526288 0.74 F11 (0.36) FAAHF11KDM4ELMNACYP3A4
SCHEMBL9737053 0.73 F11 (0.37) FAAHF11KDM4EHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2152670-B1 BRIDGED SIX-MEMBERED RING COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2013-12-25 EP disclosed
US-8202885-B2 Bridged six-membered ring compounds ACTELION PHARMACEUTICALS LTD. (CH) 2012-06-19 US disclosed
US-20100130545-A1 BRIDGED SIX-MEMBERED RING COMPOUNDS IDORSIA PHARMACEUTICALS LTD (CH) 2010-05-27 US disclosed
EP-2152670-A1 BRIDGED SIX-MEMBERED RING COMPOUNDS Actelion Pharmaceuticals Ltd. (CH) 2010-02-17 EP disclosed
WO-2008132679-A1 BRIDGED SIX-MEMBERED RING COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130545-A1 BRIDGED SIX-MEMBERED RING COMPOUNDS CACNA1E, CACNA1B, CACNA1A FAAH 2072/4885F11 909/4885RXRA 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.